Pharmacoepidemiological Research on Outcomes of Therapeutics by a European ConsorTium IMI Work Package 5: Supplement 2 to Wave 1 Case Study Report 1:b:iii: Efalizumab Multi-Criteria Decision Analysis: Decision

First Page		Document Content
Date: 2014-07-16 01:09:14 Clinical research Immunosuppressants Science Efalizumab Autoimmune diseases Progressive multifocal leukoencephalopathy Psoriasis Placebo Clinical trial Medicine Health Pharmacology		Pharmacoepidemiological Research on Outcomes of Therapeutics by a European ConsorTium IMI Work Package 5: Supplement 2 to Wave 1 Case Study Report 1:b:iii: Efalizumab Multi-Criteria Decision Analysis: Decision Add to Reading List Source URL: protectbenefitrisk.eu Download Document from Source Website File Size: 849,13 KB Share Document on Facebook

	BIOLOGICS IN THE PRACTICE OF LAW LINDSAY KELLY* Biologics have come to occupy an increasingly important role in the medical industry, accounting for well over $200 billion in worldwide sales inNot surprisingly, bi DocID: 1rrNB - View Document
	Guideline on clinical investigation of medicinal products for the treatment of Multiple Sclerosis rev. 2 DocID: 1rmwo - View Document
	EAP Reimbursement Criteria for Frequently Requested Drugs DocID: 1rhhE - View Document
	UCB Presents Latest Research from Immunology Portfolio at American College of Rheumatology Annual Meeting Data presentations include:  Positive results from Period 1 of the C-EARLY™ Phase 3 study of CIMZIA® (certol DocID: 1rakB - View Document
	TABLE OF CONTENTS INTRODUCTION 2 DocID: 1qY7G - View Document